National Results of Revascularization for Acute Coronary Syndrome in 2023

Aim    To analyze the results of myocardial revascularization in the Russian Federation (RF) for ACS in 2023 compared to previous years.
Material and methods    The analysis included the number of cases of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), myocardial revascularization in the above-listed ACS forms, the number of fatal outcomes depending on the ACS form and the revascularization method used. The data for this analysis were obtained from the 2023 Ministry of Health of Russia monitoring in the section of revascularization in ACS and were compared with the data for the past 8 years.
Results, conclusion   In 2023, 438,315 patients were hospitalized for ACS in the Russian Federation: 309,158 with NSTE-ACS and 148,729 with STEMI. The total number of hospitalizations for ACS per 1 million of the Russian population was 2,982: 1,011 with STEMI and 2,103 with NSTE-ACS. The availability of primary PCI in 2023 reached its maximum of 55.3% compared to previous years; the total number of PCI for STEMI was 75.7%, and the mortality rate in the whole STEMI group was a minimum of 10.7% for the past 8 years. In 2023, the maximum number of PCIs for NSTE-ACS for the past 8 years was recorded, both in absolute values (120,990) and in relative values (39.1%). In the whole NSTE-ACS group, mortality was 2.5%, which was also the lowest for the past 8 years.

1. Alekyan B.G., Ganyukov V.I., Manoshkina Е.М., Protopopov А.V., Skrypnik D.V., Kislukhin Т.V. Revascularization in ST-elevation myocardial infarction in the Russian Federation. Analysis of 2018 results. Russian journal of Endovascular surgery. 2019;6(2):89–97. DOI: 10.24183/2409-4080-2019-6-2-89-97

2. Alekyan B.G., Boytsov S.A., Manoshkina Е.М., Ganyukov V.I. Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016-2020. Kardiologiia. 2021;61(12):4–15. DOI: 10.18087/cardio.2021.12.n1879

3. Alekyan B.G., Boytsov S.A., Ganyukov V.I., Manoshkina Е.М. Impact of the COVID-19 Pandemic on Myocardial Revascularization in Patients with Acute Coronary Syndrome in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2022;18(4):411–9. DOI: 10.20996/1819-6446-2022-08-03

4. Alekyan B.G., Boytsov S.A., Manoshkina E.M., Ganyukov V.I. Russian national indicators of myocardial revascularization in patients with acute coronary syndrome in 2022. Endovascular Surgery. 2023;10(3):260–9. DOI: 10.24183/2409-4080-2023-10-3-260-269

5. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393

6. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289–367. DOI: 10.1093/eurheartj/ehaa575

7. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720–826. DOI: 10.1093/eurheartj/ehad191

8. Alekyan B.G., Grigoryan A.M., Staferov A.V., Karapetyan N.G. Endovascular surgery of the heart and vascular diseases in the Russian Federation - 2022. Endovascular surgery (Special Issue). 2023;10S:S5–256. DOI: 10.24183/2409-4080-2023-10S-S5-S256

9. SWEDEHEART. Annual report 2021. Av. at: https://www.ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh/1-swedeheart-annual-report-2021-english/viewdocument/3384. 2022.

10. Pereira H, Naber C, Wallace S, Gabor T, Abdi S, Alekyan B et al. Stent-Save a Life international survey on the practice of primary percutaneous coronary intervention during the COVID-19 pandemic. Revista Portuguesa de Cardiologia. 2022;41(3):221–7. DOI: 10.1016/j.repc.2021.04.006

11. Wein B, Bashkireva A, Au-Yeung A, Yoculan A, Vinereanu D, Deleanu D et al. Systematic investment in the delivery of guideline-coherent therapy reduces mortality and overall costs in patients with ST-elevation myocardial infarction: Results from the Stent for Life economic model for Romania, Portugal, Basque Country and Kemerovo region. European Heart Journal. Acute Cardiovascular Care. 2020;9(8):902–10. DOI: 10.1177/2048872619853959

12. Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M et al. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. European Heart Journal. 2021;42(44):4536–49. DOI: 10.1093/eurheartj/ehab342

13. Kristensen SD, Laut KG, Fajadet J, Kaifoszova Z, Kala P, Di Mario C et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal. 2014;35(29):1957–70. DOI: 10.1093/eurheartj/eht529

14. Stent for life. How to guide. Stent for Life is a joint initiative between the European Association of Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology (ESC), and EuroPCR. Av. at: https://www.stentsavealife.com/wp-content/uploads/2017/04/SFL-how-to-guide-1.pdf.